Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma

Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There may be a way to use this tool more effectively,” D’Incalci told The Mesothelioma Center at Asbestos.com. “We hope to deliver that eventually to patients in the clinic.” Finding the Right Treatment Synergy Tumor Treating Fields, also known as TTFields, is a novel therapy designed to disrupt cancer cell division through electrical fields tuned to specific frequencies. It is delivered through insulated adhesive pads attached to the skin. Research has shown that applying this range of alternating frequencies can disrupt certain proteins essential to cell division. It has proven to slow or stop cancer growth, and is currently used in combination with chemotherapy. In the phase III clinical trial that led to FDA approval, patients receiving TTFields and chemotherapy survived six months longer than those receiving only chemotherapy, which is the stan...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news